FDA pushes decision on Ascendis therapy for achondroplasia to February 2026

The U.S. Food and Drug Administration on November 27 extended its review of Ascendis Pharma’s investigational therapy for achondroplasia in children by three months, setting a new PDUFA decision date of February 28, 2026. Ascendis said it submitted additional information and a revised post approval study plan to address regulator questions, and that it had provided the materials requested by the agency.

The extension is a reminder of the complexity regulators face when evaluating therapies for rare pediatric conditions. Achondroplasia is the most common form of dwarfism and can affect growth, respiratory function, spine development, and mobility. Families of affected children and the clinicians who treat them have long emphasized the need for safe effective options, but regulatory scrutiny is also heightened because long term safety and developmental impacts must be understood before broad use is authorized.

For public health officials and health systems, the delay has immediate practical consequences. Payer coverage decisions commonly hinge on FDA approval. A later decision slows the timetable for insurers to decide whether to cover a new therapy, and it delays the time when hospitals and specialty clinics can adopt treatment protocols and training. In Medicaid programs and state run plans, which disproportionately serve low income and medically complex children, procurement and coverage processes can require additional administrative steps that are lengthened when a regulatory decision is postponed.

The revised post approval study plan that Ascendis submitted is a central piece of the regulatory picture. Post approval studies are intended to track safety and effectiveness over years, not months, and they are particularly important for pediatric drugs that may affect growth trajectories and neurological development. Regulators typically seek clear plans for long term monitoring, data collection from diverse patient groups, and strategies to detect rare adverse events. Those elements also matter for equity, because historically marginalized communities are often underrepresented in clinical research and may face distinct barriers to access and follow up care.

The extension also matters in the broader policy arena. Lawmakers and health policy experts are watching how the FDA balances expedited access to therapies for rare diseases with the need for evidence about long term outcomes. High cost clinics, specialty pharmacy logistics, and the potential for uneven geographic access can exacerbate disparities if a treatment reaches the market without robust plans to ensure equitable distribution and affordability.

Ascendis offered no timeline beyond the new PDUFA decision date. The company’s disclosure and industry coverage of the extension underscored the uncertainty families face while clinical and payer systems prepare for possible approval. For clinicians, the pause means continued reliance on existing supportive care strategies and monitoring practices for children with achondroplasia, while researchers and policy makers watch for the agency’s final determination and the details of any required post approval commitments.

As regulators and the company continue to exchange information, patients, families, clinicians, and advocates will be looking for clear commitments on long term safety monitoring, access safeguards for low income and rural communities, and transparent pricing and coverage pathways that can prevent new treatments from widening existing health disparities.